Cyclic GMP metabolism in psoriasis: increased activity of soluble epidermal cyclic GMP phosphodiesterase and its modulation by calcium.
Soluble cyclic GMP-phosphodiesterase was measured in normal and psoriatic epidermis. The specific activity of the enzyme was increased almost four-fold in involved compared with normal epidermis, and two- to three-fold in involved compared with uninvolved epidermis. The enzyme activity from all three sources was inhibited by 40-50% by ethylene glycol tetraacetic acid (EGTA). These results indicate that in addition to the reported enhanced capacity of psoriatic epidermis to generate cGMP, it has an increased ability to hydrolyse this nucleotide, although to a lesser degree than the augmentation found in soluble guanylate activity from psoriatic epidermis. These observations are compatible with the elevated steady-state levels of this nucleotide observed in the involved epidermis of psoriasis.
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism*; D004533:Egtazic Acid / Q000494:pharmacology; D006801:Humans; D011565:Psoriasis / Q000201:enzymology*; D012867:Skin / Q000201:enzymology*; D012995:Solubility
D004533:Egtazic Acid; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D002118:Calcium